Vesikari Comparison of Hexavalent Vaccines
Vesikari Comparison of Hexavalent Vaccines
Hexavalent Vaccines:
Hepatitis B antibody
response and
co-administration with
other vaccines
Prof. Timo Vesikari
Vaccine Research Center
University of Tampere
Tampere, Finland
Timo Vesikari
Conflicts of Interest
PI in several study protocols on
Infanrix Hexa (GSK)
Hexaxim/Hexyon (SP-MSD)
Vaxelis or PR5I (Merck)
Consultant to GSK 2016
Member (Chair) of SP-MSD Advisory Board
for Pediatric Vaccines until 2017
Consultant to Merck on PR5I until 2017
Landscape
Infanrix hexa (GSK)
- gold standard
- requires reconstitution of lyophilized Hib
component
Hexyon / Hexacim (Sanofi Pasteur)
- fully liquid
Vaxelis (Merck)
- gully liquid
Real differences in immunogenicity between the
vaccines are minor or non-existent
Infanrix hexa™ (GSK)
Clever trade name implying that
this is the basic vaccine for infants
Hexaxim / Hexyon®
(Sanofi Pasteur)
Vaxelis® (Merck)
Hexyon 0.6 mg
challenge
80
1 month post-
60 booster (HBV)
challenge
40
20
0
1 2 3
1–2 2.5–3.5 3–4 3 54 6–7
n=124;5b n=285;286b n=186;188b n=709;105b n=186;187b
3 doses given 4 doses given 4 doses given 3 doses given 4 doses given
Slovakia
Italy
Infanrix hexa™ can be given with other
vaccines
Infanrix hexa™ can be co-administered with the
following vaccines:1–12
Pneumococcal vaccines Meningococcal vaccines
Prevenar® Bexsero™
Prevenar 13® Nimenrix™
Synflorix™ NeisVac-C™
Meningitec™
Rotarix™ Priorix-Tetra™
RotaTeq® ProQuad®
Abbreviations: D: diphtheria, T: tetanus, aP: acellular pertussis, IPV: Inactivated poliovirus, Hib: Haemophilus influenzae type b, Hep B: Hepatitis B antigen
3000
2500
2000
1500
1000
500
0
Mexico
Mexico Thailand
Thailand Peru
Peru Columbia/
Colombia/Costa Rica
(A3L11)1 1
(A3L11) (A3L12)2
(A3L12)2 (A3L17)3 3
(A3L17) Rica (A3L24)4
Costa(A3L24)4
Hep B at birth Hep B at birth
H= 1022 189 132 935
C= 167 190 130 316
* Primary vaccination at 2, 4 and 6 months. Measurements made 1 month post-primary vaccination series.
† A3L11 and A3L17 participants did not receive hepatitis B vaccination at birth, whereas all A3L12 and A3L24 participants
”Similar”